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Abstract
Background: The genetic control of prostate cancer development is poorly understood. Large numbers of gene-
expression datasets on different aspects of prostate tumorigenesis are available. We used these data to identify and
prioritize candidate genes associated with the development of prostate cancer and bone metastases. Our working
hypothesis was that combining meta-analyses on different but overlapping steps of prostate tumorigenesis will
improve identification of genes associated with prostate cancer development.
Methods: A Z score-based meta-analysis of gene-expression data was used to identify candidate genes associated
with prostate cancer development. To put together different datasets, we conducted a meta-analysis on 3 levels
that follow the natural history of prostate cancer development. For experimental verification of candidates, we
used in silico validation as well as in-house gene-expression data.
Results: Genes with experimental evidence of an association with prostate cancer development were
overrepresented among our top candidates. The meta-analysis also identified a considerable number of novel
candidate genes with no published evidence of a role in prostate cancer development. Functional annotation
identified cytoskeleton, cell adhesion, extracellular matrix, and cell motility as the top functions associated with
prostate cancer development. We identified 10 genes–CDC2, CCNA2, IGF1, EGR1, SRF, CTGF, CCL2, CAV1, SMAD4, and
AURKA–that form hubs of the interaction network and therefore are likely to be primary drivers of prostate cancer
development.
Conclusions: By using this large 3-level meta-analysis of the gene-expression data to identify candidate genes
associated with prostate cancer development, we have generated a list of candidate genes that may be a useful
resource for researchers studying the molecular mechanisms underlying prostate cancer development.
Background
Gene-expression profiling has been extensively used to
classify cancers by gene-expression signatures [1-3]. It
has also been used for predicting response to treatment
[4-6] and prognosis [7-9].
Ample gene-expression data are publicly available. Two
major databases are Oncomine http://www.oncomine.org
and the Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo/). Oncomine is a rapidly growing
compendium of more than 20,000 cancer transcriptomes.
Version 3.6, as accessed on January 5, 2010, comprised
35 datasets related to different aspects of prostate tumor-
igenesis. The GEO database is part of the open National
Center for Biotechnology Information (NCBI) resources.
GEO, the largest publicly available repository of gene-
expression data [10], was established in 2000 to house
and distribute those data to researchers [11]. This
resource, however, is not generally used efficiently
because it is not obvious how to combine data from dif-
ferent sources. Meta-analysis has the potential to reduce
the biases of individual studies and may identify a repro-
ducible set of genes [12-14].
At u m o r ’s ability to invade distant sites may develop
during relatively early stages of tumorigenesis and may
be associated with the gene-expression signature in nor-
mal tissue, although the genes associated with metastatic
progression would be expected to have their highest
* Correspondence: ipgorlov@mdanderson.org
† Contributed equally
1Department of Genitourinary Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, Texas
Full list of author information is available at the end of the article
Gorlov et al. BMC Cancer 2010, 10:599
http://www.biomedcentral.com/1471-2407/10/599
© 2010 Gorlov et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.level of up-regulation or down-regulation during the
later stages. Therefore, it should be beneficial to use
data from different stages of prostate tumorigenesis to
identify genes associated with prostate cancer develop-
ment. We hypothesized that combining the gene-expres-
sion data from studies targeting different stages of
prostate tumorigenesis can reliably identify those genes
associated with prostate cancer development.
Methods
Our approach is based on the ideas that tumorigenesis is a
continuous process and that the gene-expression signature
underlying the development of bone metastases starts to
form in the early stages of prostate tumorigenesis and
becomes well developed in the later stages. We have
assumed that combining meta-analyses of different steps
of prostate carcinogenesis and assigning greater weight to
more-specific data might improve identification of genes
associated with prostate tumorigenesis, especially those
involved in the development of bone metastases; therefore,
we have up-weighted the third level of meta-analysis.
First level of the meta-analysis
T h et e n d e n c yo fp r o s t a t et u m o rt om e t a s t a s i z et ob o n e
is a hallmark of prostate tumorigenesis. Breast and lung
cancer also often metastasize to bone, although not as
frequently as prostate cancer does. Bone-metastasizing
cancers may share a gene-expression signature that pre-
disposes them to form bone metastases. On the basis of
this hypothesis, the first level of our meta-analysis
focused on comparing bone-metastasizing and non-bone
metastasizing cancers. Bone-metastasizing cancers
included breast and lung cancers. Non-bone metastasiz-
ing cancers included colorectal and ovarian cancers,
which very rarely metastasize to bone. The studies we
used are listed in Additional file 1; all of them were
aimed at identifying genes differently expressed between
normal tissue and localized tumor tissues.
For the meta-analysis, we used Rosenthal’se x t e n s i o n
of Stouffer’s method [15]. The choice of the method was
dictated by the available data: for many studies, the indi-
vidual gene-expression data points were not available,
although the t test results and corresponding p values
were readily accessible. In Z score-based meta-analysis,
the individual p value pij of gene i in study j will be con-
verted to deviate: zij = F
-1(1-pij), where F is the standard
normal cumulative distribution function. Z scores can







= ∑ 1 ,w h e r eZi is
the combined Z score for the ith gene and N is the
number of studies (datasets). The Z score is positive
when the gene is up-regulated in a more adverse pheno-
type and negative when it is down-regulated in a more
a d v e r s ep h e n o t y p e .W eu s e dt h ei n f o r m a t i o no nt h e
direction of the changes in gene expression (up- or
down-regulated from the original studies). If the gene
was down-regulated, we directly converted the p value
into a Z s c o r et op r o d u c en e g a t i v eZ values. If the gene
was up-regulated, we used 1 - p to obtain corresponding
positive Z values.
The number of studies varied for the different cancers;
e.g., 4 studies were used for breast and 9 for lung cancer.
To correct for the differences, we adjusted individual Z
scores to make the average absolute values the same
across all types of cancer. For example, the average of the
absolute values of the Z scores for breast cancer is 1.87,
and that for lung cancer is 2.85. That difference is likely a
result of the difference in sample size, i.e., 4 vs. 9 studies.
To correct for the difference in sample size, we needed to
adjust the Z scores for each probe so that the average
absolute Zs will be the same and equal to (1.87 + 2.85)/2 =
2.36. Then the adjustment factor will be 2.36/1.87 = 1.26
for breast and 2.36/2.85 = 0.83 for lung cancer. The
adjustment ensured equal contributions of individual can-
cer types to the global Z scores. This adjustment guaran-
tees that differences between bone-metastasizing and non-
bone metastasizing cancers are not driven by a single can-
cer type (e.g., lung cancer). Similar adjustments were
made for the datasets used in the second and third levels
of the meta-analysis. The sample size in individual studies
is also an important factor that directly influences the p
value: assuming the same effect size, the p value will be
smaller for studies that have a larger sample size. Since
smaller p values are transformed to larger Z scores, larger
s t u d i e sc o n t r i b u t em o r es t r o n g l yt ot h eg l o b a lZ score
than smaller studies do.
We subtracted the Z scores for the non-bone metasta-
sizing cancers from those for the bone-metastasizing
cancers. This subtraction takes away the genes that are
common in the transition from normal tissue to loca-
lized tumor in bone-metastasizing and non-bone metas-
tasizing cancer and simultaneously allows identification
of genes that are up-regulated or down-regulated in the
bone-metastasizing cancers.
Second level of the meta-analysis
Table 1 lists the datasets we used for our second-level
meta-analysis. For each gene, we computed the average
Z score by using the Z scores from our first-level meta-
analysis and those from the comparison of normal pros-
tate vs. localized prostate cancer.
Third level of the meta-analysis
Table 1 also lists the studies we used for meta-analysis
of genes expressed differently in localized and primary
metastatic prostate cancers. All datasets for localized vs.
metastatic prostate cancer comparisons are from the
Oncomine database. We followed Oncomine’s definition
of analysis that compared localized vs. metastatic
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tumor, and metastatic samples, from metastatic tumors
(bone, lung, liver, and others). For clinical details, see
the original publications indicated in Table 1. We com-
puted average Z scores by using the scores from the sec-
ond-level meta-analysis and those from meta-analysis of
gene expression in localized vs. metastatic prostate
cancer.
Functional annotation
For functional annotation, we used the Database for
Annotation, Visualization, and Integrated Discovery
(DAVID; http://david.abcc.ncifcrf.gov/) [16]. DAVID
tests the null hypothesis that genes are uniformly dis-
tributed across pathways and biologic functions.
P values characterize the strength of statistical evidence
for clustering: the lower the p value, the stronger the
evidence that the genes are overrepresented in a specific
pathway. Because our previous analyses [17,18] demon-
strated that separate functional annotation of up-
regulated and down-regulated genes tends to produce
lower p values than joint analysis does, we separately
annotated the 250 top down-regulated and the 250 top
up-regulated genes.
Proof of principle: Z scores of the genes with published
evidence of an association with prostate cancer
development
If our approach is methodologically sound, relative Z
scores for the known prostate cancer-related genes are
Table 1 Studies used for the second and third levels of our meta-analysis: genes expressed differently in the
transition from normal prostate and localized prostate cancer to metastatic disease (Oncomine datasets)
Primary author’s name PMID Tissue type (no. of samples)
Class 1 Class 2
Total no. of genes Level
Dhanasekaran 11518967 Normal prostate (22)
Primary prostate cancer (59)
9,956 2
Dhanasekaran_2 15548588 Normal adjacent prostate (12)
Prostate cancer (25)
19,650 2
Holzbeierlein 14695335 Normal prostate (4)
Prostate cancer (23)
5,854 2
Lapointe 14711987 Normal prostate (41)
Prostate carcinoma (62)
19,116 2
Luo 11406537 Benign hyperplasia (9)
Prostate carcinoma (16)
6,500 2
Nanni 16513839 Normal prostate (3)
Prostate carcinoma (22)
22,283 2
Tomlins 17173048 Benign prostate (22)
Prostate carcinoma (30)
19,355 2
Vanaja 12873976 Normal prostate (8)
Prostate adenocarcinoma (27)
44,928 2
Varambally 16286247 Benign prostate (6)
Prostate carcinoma (7)
54,675 2
Welsh 11507037 Normal prostate (9)
Prostate carcinoma (25)
11,138 2
Yu 15254046 Normal prostate (23)
Prostate carcinoma (64)
12,625 2
Dhanasekaran 11518967 Primary prostate cancer (59)
Metastatic prostate cancer (20)
9,935 3
Dhanasekaran_2 15548588 Prostate cancer (25)
Metastatic prostate cancer (6)
18,502 3
Tomlins 17173048 Prostate carcinoma (30)
Metastatic prostate cancer (19)
19,337 3
Yu 15254046 Prostate carcinoma (64)
Metastatic prostate cancer (25)
12,625 3
Vanaja 12873976 Prostate adenocarcinoma (27)
Metastatic prostate cancer (5)
44,928 3
Holzbeierlein 14695335 Prostate cancer (23)
Metastatic prostate cancer (9)
6,475 3
LaTulippe 12154061 Prostate carcinoma (23)
Metastatic prostate cancer (9)
12,600 3
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We used 2 sets of known prostate cancer-related genes–
those identified by the KnowledgeNet approach [19] and
those identified in the Gene Ontology (GO; http://www.
geneontology.org/) database–for the functions and path-
ways that are known to be involved in prostate tumori-
genesis: androgen receptor signaling, tumor growth
factor beta (TGF-b) signaling, components of the extra-
cellular matrix, cell adhesion, the Wnt signaling path-
way, and bone development. The genes from those
pathways are listed in Additional files 2 and 3.
In silico validation: primary tumors vs. distant prostate
metastases
The results of 2 studies comparing gene expression in
primary tumors and distant metastases were recently
published (GEO dataset GDS2547) [20,21]. We esti-
mated the overlap between the genes expressed differ-
ently in primary tumors vs. distant metastases and the
candidate genes our analysis identified.
Experimental validation of the candidates: clinically
advanced prostate cancer vs. benign prostatic
hypertrophy
We used in-house gene-expression data to further validate
the candidates identified by our meta-analysis. The tissue
samples were frozen surgical specimens obtained using a
protocol approved by the institutional review board of The
University of Texas MD Anderson Cancer Center. The
samples were from men undergoing cystoprostatectomies
(n = 6) and pelvic exenterations (n = 3) for clinically
advanced prostate cancer (CAPC). Seven of those 9
patients had had metastasis at the time of surgery; the
other 2 patients had developed metastatic disease shortly
after surgery. As controls, we used prostate tissues from 5
men with benign prostatic hypertrophy (BPH).
The tumor tissue samples were macrodissected from
the frozen sections, and the RNA was extracted by
using a mirVana miRNA isolation kit from Ambion, Inc.
(Austin, TX). Microarray experiments were carried out
using whole-human genome oligoarrays with 44,000 60-
mer probes (with 500 ng of total RNA starting material)
according to the manufacturer’s protocol (Agilent Tech-
n o l o g i e s ,I n c . ,S a n t aC l a r a ,C A ) .H y b r i d i z e da r r a y sw e r e
scanned with Agilent’s dual laser-based scanner, as
described previously [22].
After the quality control procedure, we had 36,549
probes for analysis. The gene-expression data were nor-
malized by using the limma package in R language http://
www.bioconductor.org. The number of unique genes was
24,829. The mean expression values were calculated
across all spots on the condition that they were mapped
to the same gene. A standard t test with equal variance
was used for calculating p values for the comparison of
the tumor and normal samples. The raw data were nor-
malized within and between arrays by using the compo-
site method of Yang et al. [23]. The false-discovery rate
was computed by using Significance Analysis of Microar-
rays software http://www-stat.stanford.edu/~tibs/SAM/.
Results
Gene-expression profile of bone-metastasizing cancers
(breast plus lung) is similar to that of prostate cancer
Z scores characterize both the direction (a positive score
means that the gene is up-regulated) and the strength of
statistical evidence (the higher the absolute value of the
Z score, the stronger the evidence). We found that the
Z scores derived from the comparison of normal and
localized tumor tissue of bone-metastasizing cancers
(breast plus lung) were much more strongly correlated
with those of the prostate cancers (normal prostate vs.
localized prostate tumor) than they were with those of
the non-bone metastasizing cancers (colon plus ovarian):
Pearson’s correlation coefficients for breast vs. prostate
cancer were 0.29, n = 9,824; for lung vs. prostate cancer,
0.36, n = 10,824; for colon vs. prostate cancer, 0.21, n =
12,756; and for ovarian vs. prostate cancer, 0.22, n =
11,984. The difference in correlation coefficients
between any bone-metastasizing and any non-bone
metastasizing cancer was significant (minimal Z test =
8.1, p < 10
-6). This supports the ideas that breast and
lung cancers have a gene-expression signature in com-
mon with that of prostate cancer.
Three-level meta-analysis
The comparison of Z scores for bone-metastasizing and
non-bone metastasizing cancers demonstrated a statisti-
cally significant positive Pearson’s correlation between
them: r = 0.33, n = 16,376, p < 10
-6. Figure 1 is a scatter
plot of the Z scores for bone-metastasizing and non-
bone metastasizing cancers. It is evident from the plot
that some genes are up-regulated in bone-metastasizing
cancers and down-regulated in non-bone metastasizing
cancers and vice versa. Those genes that are up-regu-
lated in bone-metastasizing cancers might be specifically
associated with the formation of bone metastases, which
is a hallmark of prostate carcinogenesis. The genes iden-
tified in the first and second levels of our meta-analysis
are listed in Additional files 4 and 5.
The genes and their corresponding Z scores from the
third level of analysis are listed in Additional file 6.
Functional annotation of down-regulated genes from the
third level of the analysis identified cytoskeleton, cell
adhesion, actin binding, and extracellular matrix as the
top functional categories (Additional file 7). The associa-
tions between those genes and functions remained sta-
tistically significant after application of Bonferroni’s
adjustment for multiple testing. For the up-regulated
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cant functional categories.
Z score for known prostate cancer genes
The average absolute Z score for known prostate cancer
genes was 2.06 ± 0.12, and the overall average score for
the third level of the meta-analysis was 1.53 ± 0.01. The
difference was statistically significant: t test = 6.03, df =
15,985, p < 10
-6. Table 2 shows several pathways asso-
ciated with prostate tumorigenesis. For all functional
categories except cadherins and collagens, the average Z
scores from the pathways were significantly higher than
the overall average score. The most statistically signifi-
cant differences were detected for the TGF-b signaling
pathway, integrins, androgen receptor signaling pathway,
extracellular matrix, and cell adhesion.
We separately computed average absolute Z scores for
known prostate cancer genes in each of the 3 levels of
meta-analysis. The genes identified through candidate
pathways and by the KnowledgeNet approach were ana-
lyzed separately. For both groups, the relative Z scores
increased significantly from the first to the third level of
meta-analysis (Figure 2).
Primary prostate tumor vs. distant metastasis
The genes expressed differently between primary prostate
tumor and distant metastases were derived from 2 recent
studies [20,21]. Chandran et al.[ 2 0 ]c o m p a r e dg e n e
expression in primary prostate tumor with that in distant
non-bone metastases. Figure 3, A, shows the Z-score dis-
tribution of those genes. Most of the genes that were
down-regulated in the distant metastases relative to the
primary tumor also tended to be down-regulated in our
analysis, and those up-regulated in distant metastases
tended to be up-regulated in our analysis. The mean Z
score for down-regulated genes was -2.49 ± 0.19, that for
up-regulated genes was 1.02 ± 0.15, and the overall aver-
age was 0.08 ± 0.02. Similar results were obtained for the
genes found to be differently expressed between primary
tumors and bone metastases [21] (Figure 3B).
Clinically advanced prostate cancer vs. benign prostatic
hypertrophy
We used Spearman’s correlation coefficient testing to
assess for overall consistency between the results of the
comparison of CAPC and BPH and the results of the
third-level meta-analysis. The genes shared by the 2
Figure 1 Scatter plot of bone- and non-bone metastasizing cancers. The blue line is a linear regression; the red line is a moving average
computed for 100 adjacent genes.
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the third-level meta-analysis and (b) the log ratio of
their expression values in the CAPC vs. BPH analysis.
A positive significant correlation between the ranks was
noted (r = 0.18, n = 15,503, p < 10
-6).
Discussion
Our meta-analysis integrated data from studies targeting
a number of phenotypes related to prostate cancer
development. The question is, does our meta-analysis
perform better than analysis of a single phenotype, e.g.,
localized vs. metastatic primary tumors? It is impossible
to answer this question directly because we do not have
a “correct” list of genes associated with prostate cancer
development. Indirect tests suggest that the 3-level
meta-analysis does a better job of identifying candidate
genes than the analysis of a single phenotype does. The
top genes from our meta-analysis showed stronger func-
tional clustering than did the top genes from individual
meta-analyses. For example, the average -Log(p) value
for the top 10 GO molecular functions identified by the
Table 2 Average absolute Z scores for genes from pathways and biologic functions associated with the development
of bone metastases
Function and gene category
a No. of genes
b Absolute Z score (SE) t test Degrees of freedom p value
TGF-b signaling 86 2.58 (0.34) 4.05 15,770 0.00005
Integrins 30 2.47 (0.35) 3.82 15,773 0.0001
AR signaling pathway 32 2.22 (0.34) 2.9 15,780 0.004
Components of EC matrix 64 2.11 (0.25) 3.41 15,812 0.0006
Cell adhesion 406 2.08 (0.09) 7.99 16,154 <10E-6
Wnt signaling pathway 29 2.06 (0.27) 2.13 15,777 0.03
Bone development 56 1.99 (0.24) 2.53 15,804 0.01
Collagens 40 1.76 (0.28) 1.07 15,759 0.28
Cadherins 23 1.35 (0.19) 0.61 15,767 0.54
Abbreviations: SE, standard error; TFG-b, transforming growth factor beta; AR, androgen receptor; EC, extracellular
aFunctions were defined according to the Gene Ontology database.
bA list of genes for each pathway can be found in Additional file 2.
Figure 2 Relative Z score for genes with published evidence of
an association with the development of bone metastases
based on the KnowledgeNet approach (KN) and for genes from
candidate pathways (CP). Relative Z scores were computed as the
ratio between the Z score for candidate genes and the overall
average Z score. Vertical bars represent standard error (SE).
Figure 3 Distributions of Z scores from the third-level analysis.
(A) The green line represents the distribution of all Z scores; the
blue line, the distribution of Z scores for the genes found to be
down-regulated in the study by Chandran et al. [20]; and the red
line, the distribution of genes found to be up-regulated in
Chandran’s study. (B) Distribution of Z scores of genes found to be
significantly up- and down-regulated between primary prostate
tumor and bone metastases; study by Stanbrough et al., 2006 [21].
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comparison of localized and metastatic disease (the dif-
ference was statistically significant by the nonparametric
sign test: Z = 2.9, p = 0.004). We also found that the
relative Z score for the known prostate cancer genes
increased from the first-level to the third-level meta-
analysis. The top candidates from our meta-analysis
strongly overlap with those genes that are (a) expressed
differently in primary tumors and distant metastases, (b)
involved in cancer development, and (c) expressed dif-
ferently in CAPC and BPH. Taken together, these
results suggest that our 3-level meta-analysis of the
gene-expression data is an effective tool to identify the
genes associated with prostate cancer development.
Recently Nakagawa et al. [24] published the results of a
large retrospective case-control study of systemic progres-
sion of prostate cancer (GEO dataset ID GSE10645).
Those authors identified 68 genes that are significantly
up-regulated or down-regulated in patients with relapse
defined by prostate-specific antigen concentration and sys-
temic progression (detected on positive bone or com-
puted-tomographic scanning) compared with those genes
in patients with prostate-specific antigen concentration-
defined relapse and no systemic progression. We found
that our candidate genes overlapped with genes identified
in Nakagawa’s study: the correlation coefficient between
t h ed e g r e eo fc h a n g ef r o mN a k a g a w a ’s study and the Z
scores from our analysis was 0.62, n = 58, p < 10
-6. Genes
that were significantly up-regulated after Bonferroni cor-
rection for multiple testing in both studies included
TOP2A, MKI67, CDC2, TPX2, SEC14L1, EIF2C2, THBS2,
E Z H 2 ,C D K N 3 ,B U B 1 ,P G K 1 ,C C N B 1 ,H P R T 1 ,M S R 1 ,
WDR67, CTHRC1, BIRC5, TAF2, YY1, RAD21, RAP2B,
FAM49B, SQLE, F2R, CHRAC1, INHBA, SDHC,a n d
NOX4. Significantly down-regulated genes in both studies
included PAGE4, SRD5A2,a n dAZGP1.W eh y p o t h e s i z e
that these 31 genes may be used to predict tumor progres-
sion after surgery.
One would expect that strong functional clustering of
the top candidates might be a result of gene-gene inter-
actions. To investigate this, we used Pathway Studio
software [25] to construct the network of interactions of
the top 200 genes. Only direct interactions–direct regu-
lation of gene expression, protein-protein binding, or
promoter binding–were used. We found that 96 genes
formed the network of interactions. We then selected
the genes that interacted with at least 5 other genes
from the network and whose local connectivity was at
least 2 times higher than the overall connectivity of the
gene. This method identified 10 genes: CDC2, CCNA2,
IGF1, EGR1, SRF, CTGF, CCL2, CAV1, SMAD4,a n d
AURKA. Since those genes have a large number of
downstream targets, they likely drive prostate cancer
development and consequently are the best candidates
for experimental verification.
A major limitation of this study is rooted in the avail-
able data and the fact that the genes assessed in the dif-
ferent studies only partially overlap. The studies we
used were conducted for various purposes and, as a
result, they are not absolutely homogeneous in terms of
phenotype. This is especially relevant to the comparison
of localized and metastatic cancer. Metastatic cancer
included a variety of phenotypes possessing a gene-
expression signature associated with the development of
metastases. It is likely that the genes identified in our
analysis do not completely reflect the diversity of genetic
mechanisms underlying prostate cancer development
but instead represent only the most common universal
players in prostate tumorigenesis.
Another limitation is related to the fact that different
studies use different platforms with the different sets of
genes. Because of that, in our meta-analysis, different
genes were assessed in a different number of the studies.
One can expect a higher absolute Z score for a gene
whose expression was assessed in a larger number of
studies. In accord with this expectation, we found that
the absolute Z scores positively correlated with the
number of studies we used in the meta-analysis. How-
ever, our assessments demonstrate that this correlation
is unlikely to explain more than 10% of the observed
variation in Z scores (data not shown).
Conclusions
In conclusion, our multilevel meta-analysis efficiently
combined almost all publicly available gene-expression
data on prostate cancer and allowed identification of
candidate genes associated with prostate tumor develop-
ment. The results of several in silico validation tests of
the top candidate genes suggest that they are enriched
by genes associated with prostate cancer development.
The list of candidate genes we have generated may be a
useful resource for researchers studying the molecular
mechanisms underlying prostate cancer development.
Additional material
Additional file 1: Table S1. Studies used in the first level of our meta-
analysis: bone-metastasizing vs. non-bone metastasizing cancers
(Oncomine datasets).
Additional file 2: Table S2. List of the known candidate genes for bone
metastasis identified by using the KnowledgeNet approach.
Additional file 3: Table S3. Gene Ontology-defined genes from the
pathways associated with development of bone metastasis.
Additional file 4: Table S4. Z scores in the first level of the meta-
analysis.
Additional file 5: Table S5. Z scores in the second level of the meta-
analysis.
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analysis.
Additional file 7: Table S7. Functional annotation of the top candidate
genes from the level-3 meta-analysis.
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